Skip to content
New: 100+ more US companies, including the big banks, plus insider trades from SEC filings

Health Care · NASDAQ: BIIB

Biogen: how the business works

Biogen develops, makes and sells prescription medicines, mostly for multiple sclerosis and other nerve diseases, with revenue of $9.9 billion in FY2025.

By · Checked against filings: . Editorial policy. Corrections

Follow Biogen

Email me when Biogen's page is updated after earnings.

We'll send a confirmation email first. See our privacy policy.

Biogen Inc. · Cambridge, Massachusetts · Founded 1978

Updated for Q3 FY2026 · checked

Revenue, FY2025
$9.9B
Net income, FY2025
$1.3B
Revenue, Q3 FY2026
$2.8B
Staff, end of 2025
About 7,500
Founded
1978

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

The short version

Biogen in 5 points

  1. 1 · What it sells

    Biogen sells prescription medicines, mostly for brain and nerve diseases, and its multiple sclerosis medicines brought in $4.04 billion of its $9.9 billion FY2025 revenue.

    More: what it sells

  2. 2 · Who pays it

    In FY2025, US product sales were 35.9% of Biogen's revenue, product sales outside the US 36.1%, Genentech's payments 18.8%, contract manufacturing and royalties 7.4% and the Eisai LEQEMBI share 1.8%.

    More: who pays it

  3. 3 · What it keeps from $100

    Of every $100 of revenue in FY2025, Biogen kept $13.1 as net income; it reports no operating income, and its EBITDAOperating profit before wear-and-tear charges (depreciation and amortization). As a margin: per $100 of sales. (profit before interest, tax and wear-and-tear), a Cityfort calculation, was $26.7 per $100.

    More: what it keeps from $100

  4. 4 · Where the operating profit comes from

    Biogen reports one business segment and no profit by product; multiple sclerosis medicines were 40.8% of FY2025 revenue and rare disease medicines 21.8%.

    More: where the operating profit comes from

  5. 5 · The one thing to watch

    Multiple sclerosis medicines brought in $919 million in Q3 FY2026, down from $1.06 billion a year earlier, while the Apellis medicines added $243 million.

    More: the one thing to watch

Sources: From Biogen's FY2025 10-K, Q3 FY2026 10-Q and Q3 FY2026 earnings release · checked

01Where the money goes · FY2025

Where does $100 of Biogen's money go?

Of every $100 that came in (revenue plus other income), this is where it went.

Biogen · FY2025

Receipt for every $100

Where $100 of Biogen's money went in FY2025
Cost of sales$24.3
Research and development (incl. bought-in programs)$22.7
Selling, general and administrative$24.6
Amortization, partner profit shares and other charges$9.5
Other expense, net (interest)$3.1
Income tax$2.7
Kept as net income$13.1
Total$100

Each line = amount ÷ total money in × 100. Lines may not add to exactly $100 because of rounding.

How this is worked out

Cityfort calculation from the FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $9.89 billion × 100. Biogen had no net other income that year, so revenue is all the money that came in. Research and development works out to $22.75 and is rounded down to $22.7 so the lines add to $100.

Save this receipt as an image

Embed this receipt or the key numbers

Paste this code into a blog or website to show the card you choose, with a link back to this page.

Each week: the next company due to report earnings, explained in 5 points.

No tips. Unsubscribe anytime.

We'll send a confirmation email. See our privacy policy.

02The business in one line

What does Biogen do?

Distributors buy Biogen's medicines and Genentech pays it royalties; making, researching and selling the drugs take most of that money, and $13.1 of every $100 was left as net income in FY2025.

  • In FY2025 Biogen sold $3.55 billion of medicines in the US and $3.57 billion outside it, and Genentech paid it $1.86 billion.
  • Of every $100 of FY2025 revenue, selling and administration took $24.6, making the drugs $24.3 and research, including bought-in programs, $22.7 (rounded down from $22.75 so the lines add to $100).

03Who pays it

Who pays Biogen?

  • Wholesale and specialty distributors (US)

    Share of revenue not disclosed

    Buy Biogen's medicines and resell them to pharmacies and hospitals. US product revenue was $3.55 billion in FY2025, 49.8% of product revenue.

  • Health systems and distributors outside the US

    Share of revenue not disclosed

    Buy its medicines in Europe, Asia and other regions: $3.57 billion of product revenue in FY2025, $1.87 billion of it from Europe outside Germany.

  • Genentech (Roche group)

    18.8%

    of revenue

    Pays the OCREVUS royalty and Biogen's share of US profits on RITUXAN, GAZYVA and LUNSUMIO: $1.86 billion in FY2025.

  • Contract manufacturing and royalty customers

    7.4%

    of revenue

    Companies that pay Biogen to make their drugs, or pay it other royalties: $732.9 million in FY2025.

  • Eisai (LEQEMBI partnership)

    1.8%

    of revenue

    Biogen's 50% share of LEQEMBI revenue and costs: $177.7 million in FY2025.

  • Genentech (Roche group)18.8%
  • Contract manufacturing and royalty customers7.4%
  • Eisai (LEQEMBI partnership)1.8%

How spread out the customers are

Two wholesale distributors each bought more than 10% of Biogen's total revenue in FY2025, and together they took about 43.9% of gross product revenue, up from 36.9% in FY2023. Genentech payments were 18.8% of FY2025 revenue (Cityfort calculation from the FY2025 10-K).

04How it makes money

How does Biogen make money?

Patent-protected medicines earn high profits until copies arrive, so Biogen must keep replacing them.

A new medicine is protected by patents for years, and that is when it earns most. Once generics or biosimilars launch, sales fall: TECFIDERA went from $1.01 billion in FY2023 to $680 million in FY2025. Biogen spends on research and buys companies such as Reata and Apellis to add new drugs.

Multiple sclerosis drugs, % of product revenue (Cityfort calculation from the FY2025 10-K)

64.3%56.7%

FY2023 to FY2025

  1. Research or buy a promising drug
  2. Win approval and patent protection
  3. Sell it at a high margin for years
  4. Patents end and cheaper copies arrive
  5. Sales of the old drug fall
  6. Spend the profits on the next drugs

↺ Step 6 feeds back into step 1.

05Business segments · FY2025

Which businesses make up Biogen?

  • Multiple sclerosis medicines

    40.8%

    TYSABRI, VUMERITY, TECFIDERA, AVONEX, PLEGRIDY and FAMPYRA. Biogen reports one business segment, so it gives no profit figure for any group.

    Revenue $4.0B ($4,039M)

  • Rare disease medicines

    21.8%

    SPINRAZA, SKYCLARYS and QALSODY.

    Revenue $2.2B ($2,154M)

  • Anti-CD20 programs (Genentech)

    18.8%

    OCREVUS royalty and a share of US profits on RITUXAN, GAZYVA and LUNSUMIO.

    Revenue $1.9B ($1,861M)

  • Biosimilars

    7.4%

    BENEPALI, IMRALDI, FLIXABI and others, mostly sold outside the US.

    Revenue $729M

  • Contract manufacturing, royalty and other

    7.4%

    Making drugs for other companies, plus other royalties.

    Revenue $733M

  • ZURZUVAE and other products

    2%

    ZURZUVAE for postpartum depression, plus small older products.

    Revenue $197M

  • LEQEMBI share (Eisai)

    1.8%

    Biogen's 50% share of the LEQEMBI partnership's revenue and costs.

    Revenue $178M

How the mix changed

  • Multiple sclerosis medicines
  • Rare disease medicines
  • Anti-CD20 programs (Genentech)
  • Biosimilars
  • Contract manufacturing, royalty and other
  • ZURZUVAE and other products
  • LEQEMBI share (Eisai)

Revenue by segment, FY2023 to FY2025.

US$

See the numbers
How the mix changed (US$)
YearMultiple sclerosis medicinesRare disease medicinesAnti-CD20 programs (Genentech)BiosimilarsContract manufacturing, royalty and otherZURZUVAE and other productsLEQEMBI share (Eisai)
FY2023$4.7B$1.8B$1.7B$770M$899M$11.8M$0M
FY2024$4.3B$2.0B$1.7B$793M$653M$82.5M$59.9M
FY2025$4.0B$2.2B$1.9B$729M$733M$197M$178M

06The numbers · Consolidated · US$

How has Biogen done?

Revenue

$9.9BFY2025

Revenue fell from $11.0 billion in FY2021 to $9.7 billion in FY2024 and was $9.9 billion in FY2025. Q3 FY2026 revenue of $2.8 billion was 11% above a year earlier.

US$

See the numbers
Revenue (US$)
PeriodRevenue (US$)
FY2021$11.0B
FY2022$10.2B
FY2023$9.8B
FY2024$9.7B
FY2025$9.9B
Q1 FY2024$2.3B
Q2 FY2024$2.5B
Q3 FY2024$2.5B
Q4 FY2024$2.5B
Q1 FY2025$2.4B
Q2 FY2025$2.6B
Q3 FY2025$2.5B
Q4 FY2025$2.3B
Q1 FY2026$2.5B
Q2 FY2026$2.7B
Q3 FY2026$2.8B

Net income

$1.3BFY2025

Net income was $3.0 billion in FY2022 and $1.3 billion in FY2025. Q3 FY2026 showed a $20.6 million loss, in a quarter with $283.8 million of acquired research and milestone costs.

US$

See the numbers
Net income (US$)
PeriodNet income (US$)EPS ($)
FY2021$1.6B$10.40
FY2022$3.0B$20.87
FY2023$1.2B$7.97
FY2024$1.6B$11.18
FY2025$1.3B$8.79
Q1 FY2024$393M$2.70
Q2 FY2024$584M$4.00
Q3 FY2024$389M$2.66
Q4 FY2024$267M$1.83
Q1 FY2025$241M$1.64
Q2 FY2025$635M$4.33
Q3 FY2025$467M$3.17
Q4 FY2025−$48.9M−$0.33
Q1 FY2026$320M$2.15
Q2 FY2026$97.5M$0.66
Q3 FY2026−$20.6M−$0.14

Net income for every $100 of revenue

$13.1FY2025

EBITDA is a Cityfort calculation from the FY2025 and FY2024 10-Ks (income before tax, plus other expense, net, plus depreciation and amortization), because Biogen reports no operating income line. It was $26.7 per $100 of revenue in FY2025; the FY2022 and FY2024 figures include one-off gains.

Net margin: $ of net income per $100 of revenue

See the numbers
Net income for every $100 of revenue (Net margin: $ of net income per $100 of revenue)
YearNet marginEBITDA margin
FY202114.2%–
FY202229.9%39.3%
FY202311.8%21.4%
FY202416.9%30.2%
FY202513.1%26.7%

Free cash flow

$2.1BFY2025

Free cash flow, cash from operations minus spending on property and equipment, was $3.4 billion in FY2021 and $1.1 billion in FY2022 (Cityfort calculation from the FY2021 and FY2022 10-Ks) and $2.1 billion in FY2025, as Biogen's Q4 FY2025 earnings release states.

US$ · cash from operations minus spending on plants and equipment

See the numbers
Free cash flow (US$ · cash from operations minus spending on plants and equipment)
YearCash from operationsCapital spendingFree cash flow
FY2021$3.6B$258M$3.4B
FY2022$1.4B$240M$1.1B
FY2023$1.5B$277M$1.3B
FY2024$2.9B$154M$2.7B
FY2025$2.2B$154M$2.1B
See all yearly numbers
Biogen annual financials, FY2021–FY2025, US$
YearRevenueEBITDANet incomeEPS ($)Operating cashCapexFree cash
FY2021$11.0B–$1.6B$10.40$3.6B$258M$3.4B
FY2022$10.2B$4.0B$3.0B$20.87$1.4B$240M$1.1B
FY2023$9.8B$2.1B$1.2B$7.97$1.5B$277M$1.3B
FY2024$9.7B$2.9B$1.6B$11.18$2.9B$154M$2.7B
FY2025$9.9B$2.6B$1.3B$8.79$2.2B$154M$2.1B

EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). Net income is the share belonging to the company's owners.

Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained · Stock-based compensation and dilution: pay that becomes shares

07Who runs it

Who runs Biogen, and did they deliver?

  • Christopher A. Viehbacher

    President and Chief Executive Officer · since 2022

    CEO since November 2022.

  • Robin C. Kramer

    Executive Vice President and Chief Financial Officer · since 2025

    CFO since March 2025; joined Biogen in 2018.

  • Priya Singhal

    Executive Vice President, Head of Development · since 2023

    Head of Development since January 2023. The FY2025 10-K says she rejoined Biogen in 2020 after first working there between 2012 and 2018.

  • Susan H. Alexander

    Executive Vice President, Chief Legal Officer · since 2018

    Chief Legal Officer since April 2018; joined Biogen in 2006.

  • Maria C. Freire

    Chair of the Board · since 2026

    Elected to follow Caroline Dorsa, who did not stand for re-election at the 2026 annual meeting.

What they said, and what happened

1 too early to tell · 1 delivered

  1. Said on Feb 6, 2026

    Expected FY2026 total revenue to fall by a mid-single-digit percentage from FY2025.

    What happened

    On Jul 29, 2026 Biogen changed this to a rise by a mid-single-digit percentage, and repeated it on Oct 28, 2026. Revenue for the first nine months of 2026 was $8.02 billion.

    Too early to tell
  2. Said on Apr 29, 2026

    Expected the Apellis acquisition to close in the second quarter of 2026.

    What happened

    The deal closed on May 14, 2026.

    Delivered

08What could go wrong

What could go wrong for Biogen?

  • Competition

    MS medicines losing sales to copies

    Generic TECFIDERA is sold at deep discounts, and a TYSABRI biosimilar was approved in 2023. MS revenue fell from $4.66 billion in FY2023 to $4.04 billion in FY2025; Biogen said in its FY2025 10-K (Feb 6, 2026) that it expects MS revenue to keep declining.

    Watch Quarterly MS revenue: $919 million in Q3 FY2026, against $1.06 billion a year earlier.

  • Concentration

    OCREVUS royalty halves when a biosimilar arrives

    The OCREVUS royalty was $1.41 billion in FY2025, 14.3% of revenue (Cityfort calculation from the FY2025 10-K). The tiered royalty on US OCREVUS sales falls by 50% once the first FDA-approved OCREVUS biosimilar launches; the $1.41 billion also includes a 3% royalty on OCREVUS sales outside the US.

    Watch Any FDA approval of an OCREVUS biosimilar.

  • Legal

    Patent challenge to SPINRAZA

    SPINRAZA was 15.6% of FY2025 revenue. Biogen has sued Somerset and Cipla over SPINRAZA patents, and trial is scheduled for May 2028.

    Watch Court rulings in the Delaware SPINRAZA cases.

  • Debt

    Debt and integration after Apellis

    Biogen's earnings releases put net debt at about $2.0 billion at Dec 31, 2025 and about $6.4 billion at Sep 30, 2026. Apellis integration restructuring cost about $194.7 million in the first nine months of 2026.

    Watch Debt repayment and SYFOVRE sales, which set whether up to $4.00 per right is paid to former Apellis holders.

  • Regulation

    US drug price rules

    The Inflation Reduction Act lets Medicare negotiate prices for some high-cost drugs: Part D from 2026 and Part B from 2028. Biogen's 10-Q also notes US actions on MFN (most-favored-nation) pricing that have been issued or proposed.

    Watch Any Biogen medicine named for Medicare price negotiation in its filings.

  • Execution

    Drug trials may fail

    Growth depends on new drugs. Biogen expensed $471.8 million on acquired research programs in FY2025 and $283.8 million in Q3 FY2026 alone.

    Watch Phase 3 lupus results for litifilimab, due in the first half of December 2026, the company said.

  • Concentration

    Two distributors take a large share

    Two wholesale distributors together accounted for about 43.9% of gross product revenue in FY2025.

    Watch This share in the next 10-K.

09Supporters vs. critics

What do supporters and critics point to?

Facts each side points to. We don't say which side is right.

What supporters point to

  • Revenue was $2.80 billion in Q3 FY2026, 11% above the $2.53 billion of Q3 FY2025.
  • SPINRAZA sales were $461 million in Q3 FY2026, up from $374 million, after the FDA approved a higher-dose regimen in March 2026.
  • SKYCLARYS, which came with Reata in 2023, grew from $55.9 million of sales in FY2023 to $520.5 million in FY2025.
  • The Apellis medicines SYFOVRE and EMPAVELI added $243 million of revenue in Q3 FY2026.
  • Free cash flow was about $2.1 billion in FY2025, Biogen's Q4 FY2025 earnings release states.

What critics point to

  • Multiple sclerosis medicines brought in $919 million in Q3 FY2026, down from $1.06 billion a year earlier. Generic TECFIDERA and a TYSABRI biosimilar compete with them.
  • The tiered royalty on US OCREVUS sales falls by 50% once the first FDA-approved OCREVUS biosimilar launches. The OCREVUS royalty was $1.41 billion in FY2025.
  • Net debt was about $6.4 billion at Sep 30, 2026, up from about $2.0 billion at Dec 31, 2025, Biogen's earnings releases say.
  • Biogen reported a net loss of $20.6 million in Q3 FY2026, a quarter with $283.8 million of acquired research and milestone costs.
  • Revenue was $11.0 billion in FY2021 and $9.9 billion in FY2025.

10What to watch next

What should you watch next at Biogen?

Next event

Q4 FY2026 results

Date not announced yet.

  • Lupus trial results

    Biogen said on Oct 28, 2026 that Phase 3 results for litifilimab in lupus (TOPAZ-1 and TOPAZ-2) are due in the first half of December 2026.

  • MS sales each quarter

    MS medicines brought in $919 million in Q3 FY2026, against $1.06 billion a year earlier. Biogen said in its FY2025 10-K that it expects MS revenue to keep declining.

  • An OCREVUS biosimilar

    Once the first FDA-approved OCREVUS biosimilar launches, the tiered royalty on US OCREVUS sales falls by 50%. The OCREVUS royalty was $1.41 billion in FY2025.

  • SYFOVRE sales and debt

    SYFOVRE sold $191.3 million in Q3 FY2026, and its sales set whether former Apellis holders get up to $4.00 more per share. Net debt was about $6.4 billion at Sep 30, 2026.

11Key dates

What are the key dates for Biogen?

Dates as stated in the filings. A date that no filing has given yet shows as not yet stated.
Key dates for Biogen
EventDateSource
Litifilimab Phase 3 lupus results (TOPAZ-1 and TOPAZ-2)Due in the first half of December 2026, Biogen said on Oct 28, 2026.Not yet statedQ3 FY2026 earnings release (Form 8-K, Exhibit 99.1)
IMRALDI patent validity hearing in GermanySet for February 2027.Not yet statedForm 10-Q for Q3 FY2026
SPINRAZA patent trial against Somerset and CiplaScheduled for May 2028.Not yet statedForm 10-Q for Q3 FY2026

12Key facts

Key facts about Biogen

What does Biogen do?
Biogen Inc. develops, makes and sells prescription medicines, mostly for diseases of the brain and nerves such as multiple sclerosis (MS) and spinal muscular atrophy. Its MS medicines brought in $4.04 billion of its $9.89 billion revenue in FY2025.
How does Biogen make money?
Biogen makes most of its money by selling its own medicines: product sales were 72.0% of its FY2025 revenue, 35.9% in the US and 36.1% elsewhere. Genentech's royalties and profit shares were 18.8%, contract manufacturing and royalties 7.4% and Biogen's LEQEMBI share 1.8% (Cityfort calculation from the FY2025 10-K).
Who are Biogen's customers?
In the US Biogen sells mainly to wholesale and specialty distributors and specialty pharmacies; elsewhere to wholesale distributors, hospitals, pharmacies and distribution partners. Two wholesale distributors together took about 43.9% of Biogen's gross product revenue in FY2025, and Genentech paid Biogen $1.86 billion that year.
How big is Biogen?
Biogen had revenue of $9.89 billion and net income of $1.29 billion in FY2025, and about 7,500 employees at Dec 31, 2025. In Q3 FY2026 Biogen's revenue was $2.80 billion, with a net loss of $20.6 million.
Who owns Biogen?
Biogen has one class of common stock and no controlling holder. Its 2026 proxy statementThe yearly filing about shareholder votes, the board and executive pay. Learn more lists PRIMECAP Management at 10.1% (13G/A filed Nov 13, 2025), BlackRock at 8.5% (Apr 17, 2025), FMR at 6.4% (Feb 5, 2026) and State Street at 5.0% (Nov 10, 2025). Biogen's directors and executive officers held about 0.2% on Apr 21, 2026 (Cityfort calculation from the proxy).
Does Biogen pay a dividend?
Biogen has never paid a cash dividend. Its 2020 buyback program allows up to $5.0 billion of share repurchases, and about $2.1 billion of it was left at Dec 31, 2025.
What did Biogen buy in 2026?
Biogen bought Apellis Pharmaceuticals on May 14, 2026 for $41.00 a share in cash, about $5.3 billion. The deal added the eye drug SYFOVRE and the rare-disease drug EMPAVELI, which sold $191.3 million and $51.5 million in Q3 FY2026.
How much debt does Biogen have?
Biogen's Q3 FY2026 earnings release puts its debt at about $7.7 billion and its net debt at about $6.4 billion at Sep 30, 2026. Its Q4 FY2025 release put net debt at about $2.0 billion at Dec 31, 2025.

Terms on this page

Each explains the term in plain English, with the same number from other companies on Cityfort.

Go deeper

More detail from the same filings. Open any section.

13What it sells

13What it sells

What does Biogen sell?

Biogen invents, makes and sells prescription medicines, mostly for diseases of the brain and nerves. Its biggest group treats multiple sclerosis (MS), where the immune system attacks the nerves. It also earns royalties and profit shares on drugs that partners sell.
  • Multiple sclerosis medicines

    TYSABRI, VUMERITY, TECFIDERA, AVONEX and PLEGRIDY, sold to treat MS. Together they brought in $4.04 billion in FY2025, down from $4.66 billion in FY2023.

  • SPINRAZA

    A drug for spinal muscular atrophy (SMA), an inherited disease that weakens muscles. Sales were $1.55 billion in FY2025; the FDA approved a higher-dose regimen in March 2026.

  • SKYCLARYS and QALSODY

    SKYCLARYS treats Friedreich ataxia, a rare inherited nerve disease, and came with the 2023 purchase of Reata. QALSODY treats a genetic form of ALS (SOD1-ALS). FY2025 sales were $520.5 million and $86.9 million.

  • SYFOVRE and EMPAVELI

    Bought with Apellis in May 2026. SYFOVRE treats geographic atrophy, an immune-driven disease of the retina; EMPAVELI treats a rare blood disorder (PNH) and two kidney diseases. They sold $191.3 million and $51.5 million in Q3 FY2026.

  • LEQEMBI

    An Alzheimer's antibody developed and sold with Japan's Eisai. Biogen books its 50% share of the partnership's revenue and costs, $177.7 million in FY2025.

  • ZURZUVAE

    A pill for postpartum depression, sold in the US with Supernus, which takes half of the US profit or loss. Sales were $195.1 million in FY2025.

  • Biosimilars

    Near-copies of other companies' biologic drugs (medicines made in living cells), such as BENEPALI and IMRALDI, sold by Biogen mostly in Europe; Samsung Bioepis makes IMRALDI. Sales were $729.1 million in FY2025.

  • Anti-CD20 programs with Genentech

    A royalty on US sales of Genentech's MS drug OCREVUS ($1.41 billion in FY2025) plus a share of US profits on RITUXAN, GAZYVA and LUNSUMIO ($420.2 million).

What it does

  • Does: Sells its own medicines through wholesalers, specialty distributors and specialty pharmacies in the US, and through its own sales teams worldwide.
  • Does: Collects a tiered royalty from Genentech on US sales of OCREVUS, from 13.5% up to 24.0%.
  • Does: Makes biologic drugs in its own plants, including a large plant in Solothurn, Switzerland, and makes drugs for other companies under contract.

What it does not do

  • Does not: Does not sell OCREVUS itself: Genentech sells it and pays Biogen a royalty.
  • Does not: Does not book all of LEQEMBI's sales: Eisai records them, and Biogen books half of the partnership's revenue and costs.
  • Does not: Does not sell biosimilars much in the US: $13.7 million of the $729.1 million in FY2025 came from US sales.
14How the money flows

14How the money flows · FY2025

How does money flow through Biogen?

Money in

  • Total revenue (medicines, Genentech payments, LEQEMBI share, manufacturing and royalties)$9.9B

The company

Biogen

$9.9B came in

Money out

  • Cost of sales (making and supplying medicines, royalties paid)$2.4B
  • Research and development, incl. $471.8M for bought-in drug programs$2.3B
  • Selling, general and administrative$2.4B
  • Amortization of bought drug rights, partner profit shares and other charges$940M
  • Other expense, net (interest and investment results)$306M
  • Income tax$264M
  • Net income$1.3B
  1. Customers and partners paid Biogen $9.89 billion in FY2025; $7.12 billion was for its own medicines.
  2. Making and supplying the medicines took $2.40 billion.
  3. Research took $2.25 billion, including $471.8 million paid for drug programs bought from others. Selling and administration took $2.43 billion.
  4. Amortization of drug rights bought in past deals ($515.0 million), partners' profit shares, restructuring and write-downs took $940.3 million more. Interest and other items took $305.6 million.
  5. Tax took $263.6 million, and $1.29 billion was left as net income.
15What it needs to run

15What it needs to run

What does Biogen need to run?

  • Research and bought-in drug programs

    New drugs replace old ones whose patents end. Biogen spent $1.78 billion on research and $471.8 million on acquired programs in FY2025, and bought RayThera in August 2026.

  • Patents and orphan drug status

    Patents, and orphan drug status for rare-disease medicines, keep copies off the market for a time. SPINRAZA has orphan drug designation in the US, the EU and Japan; SKYCLARYS and QALSODY in the US and the EU.

  • Biologics plants

    Its Solothurn, Switzerland plant is approved to make LEQEMBI and TYSABRI. About $2.0 billion of its $3.32 billion of long-lived assets related to Solothurn at Dec 31, 2025.

  • Partners

    Genentech (OCREVUS royalty), Eisai (LEQEMBI), Supernus (ZURZUVAE) and Samsung Bioepis (biosimilars) each share revenue or profit with Biogen.

  • People

    About 7,500 employees at Dec 31, 2025.

16Where it sells

16Where it sells · FY2025

Where does Biogen sell?

  • United States (share of product revenue)49.8%
  • Europe excluding Germany (share of product revenue)26.3%
  • Germany (share of product revenue)12%
  • Asia (share of product revenue)5.9%
  • Other regions (share of product revenue)6%
17Competitors and what protects it

17Competitors and what protects it

Who does Biogen compete with?

Biogen sells medicines for MS and rare nerve diseases. Its FY2025 10-K calls competition in MS "intense" and says cheaper generics have cut its TECFIDERA revenue.
  • Eli Lilly and Company

    NYSE: LLY

    Its Alzheimer's drug KISUNLA, approved in the US in 2024 and the EU in 2025, competes with LEQEMBI, the 10-K says.

  • EVRYSDI and ZOLGENSMA (SMA treatments)

    The 10-K names this oral drug and this gene therapy as competitors to SPINRAZA, and expects them in more countries.

  • Generic TECFIDERA makers (e.g. Neuraxpharm)

    Generic versions sell at deep discounts in North America, Brazil and parts of Europe. Biogen has sued some makers, including Neuraxpharm, for damages over EU sales.

  • TYSABRI biosimilar

    A biosimilar of TYSABRI was approved in the US and the EU in 2023. Biogen said in its Q3 FY2026 10-Q (Oct 28, 2026) that it expects the biosimilar to keep hurting TYSABRI sales.

  • Somerset Therapeutics and Cipla

    Biogen sued both in May and June 2026 under the Hatch-Waxman Act over SPINRAZA patents; trial is scheduled for May 2028.

What protects the business

Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.

  • Patents and orphan drug status3 of 5

    SPINRAZA has orphan drug designation in the US, the EU and Japan, and SKYCLARYS and QALSODY in the US and the EU. TECFIDERA shows the limit: its sales fell from $1.01 billion in FY2023 to $680 million in FY2025 as generics spread.

  • Biologics manufacturing3 of 5

    It owns large plants, including Solothurn in Switzerland, approved to make LEQEMBI and TYSABRI, and earned $732.9 million in FY2025 from contract manufacturing, royalties and other revenue.

  • Partner income3 of 5

    The Genentech programs paid $1.86 billion in FY2025 without Biogen selling those drugs, but the OCREVUS royalty halves when the first FDA-approved OCREVUS biosimilar launches.

Weak spot

Aging MS medicines

MS drugs were 56.7% of FY2025 product revenue, and MS revenue fell from $4.66 billion in FY2023 to $4.04 billion in FY2025. Management said in the FY2025 10-K that it expects MS revenue to keep declining.

18Where growth could come from

18Where growth could come from

Where could Biogen's growth come from?

Biogen said in its Q3 FY2026 earnings release (Oct 28, 2026) that it expects FY2026 total revenue to rise by a mid-single-digit percentage from 2025, and non-GAAPThe company's own "adjusted" numbers, not the official (GAAP) ones. Always read them next to the official figure. Learn more diluted EPS (Biogen's adjusted profit per share) of $12.20 to $13.00. That EPS range includes about $3.20 per share of acquired research, upfront and milestone costs and $0.55 of expected dilution from Apellis. On Feb 6, 2026, before agreeing to buy Apellis, it had said revenue would fall by a mid-single-digit percentage and non-GAAP EPS would be $15.25 to $16.25.
Management statement, Oct 28, 2026. Reported as a statement, not our forecast.
  • SPINRAZA higher dose

    Working

    $461M in Q3 FY2026, up from $374M

    The FDA approved a higher-dose regimen in March 2026. In its Q3 release Biogen said conversion to it "continues to exceed Company expectations".

    Status: Working, on track against what the company said.

  • Apellis medicines (SYFOVRE, EMPAVELI)

    New

    $243M of revenue in Q3 FY2026

    Bought on May 14, 2026 for $41.00 a share in cash, about $5.3 billion, plus a right to up to $4.00 more per share if SYFOVRE sales pass set levels.

    Status: New, recently announced.

  • LEQEMBI (with Eisai)

    Working

    Biogen's share $68M in Q3 FY2026, up from $43M

    Eisai recorded global LEQEMBI sales of $202 million in Q3 FY2026, up from $121 million. The FDA approved an under-the-skin autoinjector for the starting dose in July 2026.

    Status: Working, on track against what the company said.

  • SKYCLARYS

    Working

    $178M in Q3 FY2026, up from $133M

    Came with Reata in September 2023. Yearly sales rose from $55.9 million in FY2023 to $520.5 million in FY2025.

    Status: Working, on track against what the company said.

  • ZURZUVAE

    Working

    $84M in Q3 FY2026, up from $55M

    Approved in the US in August 2023 and the EU in September 2025. Supernus shares half of the US profit or loss.

    Status: Working, on track against what the company said.

  • Late-stage pipeline

    Early

    Lupus results due first half of Dec 2026

    Biogen said on Oct 28, 2026 that Phase 3 results for litifilimab in lupus (TOPAZ-1 and TOPAZ-2) are due in the first half of December 2026, with felzartamab results in the first half of 2027.

    Status: Early, too early to judge.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

19The company's own measures (non-GAAP)

19The company's own measures · FY2024, FY2025 and Q3 FY2026

What do Biogen's own measures show?

Adjusted (non-GAAP) figures are Biogen's own measures, shown next to the GAAP figure they start from. The rest of this page uses GAAP figures.
  • Official (GAAP): Diluted EPS, FY2025

    $8.79

    Company's own measure: Non-GAAP diluted EPS, FY2025

    $15.28

    Biogen leaves out acquisition costs such as amortization of drug rights and inventory step-up, restructuring, and gains or losses on equity investments.

  • Official (GAAP): Diluted EPS, FY2024

    $11.18

    Company's own measure: Non-GAAP diluted EPS, FY2024

    $16.47

    Same type of exclusions.

  • Official (GAAP): Diluted EPS, Q3 FY2026

    −$0.14

    Company's own measure: Non-GAAP diluted EPS, Q3 FY2026

    $2.62

    Same type of exclusions, including Apellis deal costs. Both figures include $284 million of acquired research and milestone costs, mainly for RayThera.

These are the company's own measures, defined by the company. They are not comparable across companies, and they are not added together. Each sits beside the nearest official (GAAP) figure.

Learn: Non-GAAP measures: what a company's "adjusted" numbers leave out

20Financial strength and debt

20Financial strength · Sep 30, 2026

How much debt does Biogen have?

Biogen's Q3 FY2026 earnings release puts net debt, debt minus cash, at about $6.4 billion at Sep 30, 2026; its Q4 FY2025 earnings release put it at about $2.0 billion at Dec 31, 2025.
  • Total debt$7.7B
  • Cash and investments$1.3B
  • Net debt (debt minus cash)$6.4B
  • Net worth (shareholders' money)$18.9B
Debt to equity
0.41×
$ of debt for every $1 of shareholders' money
  • Biogen's Q3 FY2026 earnings release puts debt at about $7.7 billion and cash and cash equivalents at about $1.3 billion at Sep 30, 2026. The Q3 FY2026 10-Q shows $7,292.0 million of notes payable plus a $400.0 million current portion of notes and term loan, and no marketable securities that day.
  • At Dec 31, 2025 Biogen had about $4.2 billion of cash, cash equivalents and marketable securities and about $6.3 billion of debt, its Q4 FY2025 earnings release and Q3 FY2026 10-Q state. The FY2025 10-K shows $6,286.8 million of notes.
  • Biogen paid for Apellis with cash and marketable securities, a $2.0 billion term loan and a $400.0 million draw on its revolving credit line, the Q3 FY2026 10-Q says.
  • It also took over Apellis's term loan with Sixth Street Lending Partners, about $395.2 million including interest and prepayment fees, and repaid it in full in Q2 FY2026.
  • At Dec 31, 2025 Biogen's seven series of notes carried interest rates from 2.250% (due 2030) to 6.450% (due 2055). Interest expense was $267.5 million in FY2025.
  • Of the $6,567.3 million of note principal at Dec 31, 2025, none was due from 2026 to 2029, $1,500.0 million was due in 2030 and $5,067.3 million in 2031 or later, the FY2025 10-K shows.
  • Goodwill and intangible assets were $20.4 billion, 63.6% of total assets of $32.1 billion at Sep 30, 2026. Debt was 0.41 times equity. Both are Cityfort calculations from the Q3 FY2026 10-Q.
21Who owns it

21Who owns it · ownership as of Apr 21, 2026

Who owns Biogen?

Biogen has one class of stock with one vote per share, and no holder controls it. The 20 directors and executive officers held 259,975 shares plus 107,827 options and stock units, about 0.2% (Cityfort calculation from the 2026 proxy statement, record date Apr 21, 2026).
Officers and directors (as a group), shares
0.2%
Share classes
Biogen share classes: shares outstanding (millions) and votes per share
ClassShares (millions)Votes per shareHeld by% of shares% of votesTraded
Common stock (147,820,223 shares on Oct 26, 2026 (Q3 FY2026 10-Q cover). Biogen has one class of common stock.)147.81–––Yes
Holders of 5% or more
Biogen holders of 5% or more, from the proxy statement or later Schedule 13G filings; each row shows its own date
HolderSharesVotesAs ofSourceNote
PRIMECAP Management Company10.1%–Nov 13, 2025S15Proxy figure from a Schedule 13G/A filed Nov 13, 2025 (14,954,697 shares on Sep 30, 2025).
BlackRock, Inc.8.5%–Apr 17, 2025S15Proxy figure from a Schedule 13G/A filed Apr 17, 2025 (12,506,681 shares). This is older data.
FMR LLC6.4%–Feb 5, 2026S15Proxy figure from a Schedule 13G filed Feb 5, 2026 (9,413,062 shares on Dec 31, 2025).
State Street Corporation5.0%–Nov 10, 2025S15Proxy figure from a Schedule 13G filed Nov 10, 2025 (7,321,168 shares).

From the company's proxy statement (DEF 14A), later Schedule 13G filings and the share counts on its latest annual or quarterly report. Each holder row shows the date of its own filing.

Learn: How to read a proxy statement (DEF 14A): Nvidia's 2026 proxy · Form 4 insider filings: who files, the codes and the footnotes

22What it does with profit

22What it does with profit

What does Biogen do with its profit?

Biogen has never paid a cash dividend. Its 2020 buyback program allows up to $5.0 billion of repurchases with no end date; about $2.1 billion was left at Dec 31, 2025, and it bought no shares in Q4 FY2025.

No buybacks or fund raises in the period covered.

23Governance signals

23Governance signals

What do Biogen's governance filings show?

Auditor
PricewaterhouseCoopers LLP, since 2003
Auditor changes
None in the period covered
Audit qualifications
None reported
Related-party dealings
The 2026 proxy statement describes a written policy under which the board's Corporate Governance Committee must review and approve any transaction in which a director, executive officer or family member has a material interest.
Credit rating
Not checked for this page

Flags to know about

  • other · Oct 28, 2026

    Securities class actions

    Biogen and some current and former officers are or were defendants in four securities actions. They allege violations of federal securities laws over statements about ADUHELM, LEQEMBI, TECFIDERA and VUMERITY, and statements Apellis made about SYFOVRE. According to the Q3 FY2026 10-Q, in September 2026 a court gave final approval to the settlement of one action and in October 2026 preliminary approval to the settlement of another. One action was dismissed in March 2026 and the appeal continues; in August 2026 an appeals court affirmed the dismissal of another.

  • other · Oct 28, 2026

    IMRALDI patent dispute in Europe

    Fresenius Kabi alleges that IMRALDI infringes its EP '488 patent. It seeks about EUR 19.1 million in damages in France, and a German validity hearing is set for February 2027.

24How it got here

24How it got here

How did Biogen get here?

  1. 1978

    Milestone

    Founded

    Biogen was founded in 1978.

  2. 2023

    Business-model change

    Fit for Growth and Reata

    Started Fit for Growth, a cost program, and in September bought Reata, which brought SKYCLARYS.

  3. 2023

    Crisis

    TYSABRI biosimilar approved

    A copy of TYSABRI, its biggest MS drug, was approved in the US and the EU.

  4. 2025

    Crisis

    TECFIDERA patent revoked in Europe

    In November 2025 the European Patent Office revoked a TECFIDERA patent, and Biogen stopped enforcing it and its national counterparts.

  5. 2026

    Milestone

    SPINRAZA higher dose approved

    The FDA approved a higher-dose SPINRAZA regimen in March 2026.

  6. 2026

    Business-model change

    Apellis bought

    Closed the Apellis deal on May 14, 2026, adding SYFOVRE for an eye disease and EMPAVELI for rare blood and kidney diseases.

25Sources and changes

Where every number on this page comes from

Sources (22 documents)
  1. S1Form 10-Q for Q3 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Oct 28, 2026
  2. S2Form 10-Q for Q2 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Jul 29, 2026
  3. S3Form 10-Q for Q1 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Apr 29, 2026
  4. S4Form 10-K for FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Feb 6, 2026
  5. S5Form 10-Q for Q3 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Oct 30, 2025
  6. S6Form 10-Q for Q2 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Jul 31, 2025
  7. S7Form 10-Q for Q1 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · May 1, 2025
  8. S8Form 10-K for FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Feb 12, 2025
  9. S9Form 10-Q for Q3 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Oct 30, 2024
  10. S10Form 10-Q for Q2 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Aug 1, 2024
  11. S11Form 10-Q for Q1 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Apr 24, 2024
  12. S12Form 10-K for FY2023 · SEC EDGAR · Tier 1: company or exchange filing · Feb 14, 2024
  13. S13Form 10-K for FY2022 · SEC EDGAR · Tier 1: company or exchange filing · Feb 15, 2023
  14. S14Form 10-K for FY2021 · SEC EDGAR · Tier 1: company or exchange filing · Feb 3, 2022
  15. S15Proxy statement (DEF 14A) for the 2026 annual meeting · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Apr 28, 2026
  16. S16Q3 FY2026 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Oct 28, 2026
  17. S17Q2 FY2026 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Jul 29, 2026
  18. S18Q1 FY2026 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Apr 29, 2026
  19. S19Q4 FY2025 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Feb 6, 2026
  20. S20Q4 FY2024 earnings release (Form 8-K, Exhibit 99.1) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Feb 12, 2025
  21. S22Form 8-K: Apellis acquisition completed, CVR agreement and credit agreement · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · May 14, 2026
  22. S23Form 8-K: board chair change (Items 5.02 and 8.01) · Biogen Inc. (SEC EDGAR) · Tier 1: company or exchange filing · Feb 11, 2026
Changes to this page (v1 · Nov 20, 2026)
  1. v1 · Nov 20, 2026First version. (first version)

Numbers come only from tier 1 and tier 2 sources. Read how we research.

Disclaimer

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.

Read the positions policy
Read the full disclaimer

Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.

All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.